Literature DB >> 3669065

Interaction of [3H]dipyridamole with the nucleoside transporters of human erythrocytes and cultured animal cells.

C Woffendin1, P G Plagemann.   

Abstract

Equilibrium binding of [3H]dipyridamole identified high-affinity (Kd approximately 10 nM) binding sites on human erythrocytes (approximately 5 X 10(5) sites/cell) and on HeLa cells (approximately 5 X 10(6) sites/cell). The equilibration of dipyridamole with these sites on human erythrocytes was compatible with a second-order process which proceeded at 22 degrees C with a rate constant of about 6 X 10(6) M-1 sec-1. Binding of dipyridamole to these sites correlated kinetically with the inhibition of the equilibrium exchange of 500 microM uridine in these cells and was inhibited in a concentration-dependent manner by nucleosides and other inhibitors of nucleoside transport, such as nitrobenzylthioinosine, dilazep and lidoflazine, but not by hypoxanthine, which is not a substrate for the nucleoside transporter of human erythrocytes. The results indicate that the substrate binding site of the transporter is part of the high-affinity dipyridamole binding site. Bound [3H]dipyridamole became displaced from these sites on human erythrocytes by incubation with an excess of unlabeled dipyridamole or high concentrations of nucleosides and inhibitors of nucleoside transport, but neither by hypoxanthine nor sugars. Dissociation of [3H]dipyridamole behaved as a simple first-order process, but the rate constant was about one order of magnitude lower (about 3 X 10(-3) sec-1) than anticipated for typical ligand-protein binding on the basis of the measured association rate and equilibrium constants. The reason for this discrepancy has not been resolved. No high-affinity dipyridamole binding sites were detected on Novikoff rat hepatoma cells, P388, L1210 and S49 mouse leukemia cells or Chinese hamster ovary cells, and their absence correlated with a greater resistance of nucleoside transport in these cells to inhibition by dipyridamole. All cells expressed considerable low affinity (Kd greater than 0.5 microM) and nonspecific binding of dipyridamole.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669065     DOI: 10.1007/bf01871048

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  39 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Kinetics of nucleoside transport in human erythrocytes. Alterations during blood preservation.

Authors:  P G Plagemann; R M Wohlhueter
Journal:  Biochim Biophys Acta       Date:  1984-11-21

3.  [3H]dipyridamole: a new ligand probe for brain adenosine uptake sites.

Authors:  P J Marangos; M Houston; P Montgomery
Journal:  Eur J Pharmacol       Date:  1985-11-19       Impact factor: 4.432

4.  Nucleoside transport in Walker 256 rat carcinosarcoma and S49 mouse lymphoma cells. Differences in sensitivity to nitrobenzylthioinosine and thiol reagents.

Authors:  J A Belt; L D Noel
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

5.  Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine.

Authors:  P G Plagemann; M Kraupp
Journal:  Biochem Pharmacol       Date:  1986-08-01       Impact factor: 5.858

6.  Nucleoside transport in human erythrocytes. Nitrobenzylthioinosine binding and uridine transport activities have similar radiation target sizes.

Authors:  S M Jarvis; D A Fincham; J C Ellory; A R Paterson; J D Young
Journal:  Biochim Biophys Acta       Date:  1984-05-16

7.  Nitrobenzylthioinosine-sensitive and -resistant nucleoside transport in normal and transformed rat cells.

Authors:  P G Plagemann; R M Wohlhueter
Journal:  Biochim Biophys Acta       Date:  1985-06-27

8.  Nucleoside transport in cultured mammalian cells. Multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine.

Authors:  P G Plagemann; R M Wohlhueter
Journal:  Biochim Biophys Acta       Date:  1984-06-13

9.  Nucleoside transport in human erythrocytes. A simple carrier with directional symmetry in fresh cells, but with directional asymmetry in cells from outdated blood.

Authors:  S M Jarvis; J R Hammond; A R Paterson; A S Clanachan
Journal:  Biochem J       Date:  1983-02-15       Impact factor: 3.857

10.  Adenosine metabolism in wild-type and enzyme-deficient variants of Chinese hamster ovary and Novikoff rat hepatoma cells.

Authors:  P G Plagemann; R M Wohlhueter
Journal:  J Cell Physiol       Date:  1983-08       Impact factor: 6.384

View more
  5 in total

1.  Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

Authors:  J Szebeni; S M Wahl; M Popovic; L M Wahl; S Gartner; R L Fine; U Skaleric; R M Friedmann; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Plasmodium falciparum Parasite Proliferation.

Authors:  Yvett Sosa; Roman Deniskin; I J Frame; Matthew S Steiginga; Deepak Bandyopadhyay; Todd L Graybill; Lorena A Kallal; Michael T Ouellette; Andrew J Pope; Katherine L Widdowson; Robert J Young; Myles H Akabas
Journal:  ACS Infect Dis       Date:  2019-08-14       Impact factor: 5.084

3.  Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Differential uptake of [3H]guanosine by nucleoside transporter subtypes in Ehrlich ascites tumour cells.

Authors:  J R Hammond
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

5.  Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

Authors:  N J Curtin; K J Bowman; R N Turner; B Huang; P J Loughlin; A H Calvert; B T Golding; R J Griffin; D R Newell
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.